PCSK1 and systemic inflammatory response syndrome: With activity to attenuate TNF-induced systemic inflammatory response syndrome (SIRS) and brain I/R injury after oral administration, this compound can also synergize with other inhibitors of necroptosis, including TAK632 (a RIPK1/3 inhibitor), SZM630 (a RIPK3 inhibitor), Nec-1 (a RIPK1 inhibitor), and NSA (an MLKL inhibitor).